Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-centre, multi-national, phase 3, randomized, double-blind, double-dummy, 3-arm parallel group, placebo- and pramipexole-controlled trial of the efficacy and safety of rotigotine patch in subjects with advanced stage, idiopathic Parkinson's disease who are not well controlled on levodopa.

Next Previous
X
Search
Trial Profile

A multi-centre, multi-national, phase 3, randomized, double-blind, double-dummy, 3-arm parallel group, placebo- and pramipexole-controlled trial of the efficacy and safety of rotigotine patch in subjects with advanced stage, idiopathic Parkinson's disease who are not well controlled on levodopa.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rotigotine (Primary) ; Pramipexole
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Acronyms CLEOPATRA-PD
  • Sponsors UCB

    • Most Recent Events

    • 08 Jun 2017 Results of post hoc analysis of pooled data from 6 placebo contolled trials (SP506, SP512, SP513, SP515, SP650, and SP921) presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
    • 08 Jun 2017 Results of post-hoc pooled analysis from patients who received levodopa doses in 8 randomized placebo-controlled studies, presented at the 21st International Congress of Parkinson's Disease and Movement Disorders.
    • 12 Feb 2016 Results of pooled post-hoc analysis of this and two other trials (see profile 26754 and 169511) published in the Clinical Neuropharmacology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top